Drug Patents owned by Recordati Rare

1. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(6 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(8 years from now)

CN105440038A RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Feb, 2019

(3 years ago)

CN101248078B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN102408429A RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole And Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN101248078A RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

CN102408429B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN102711916B RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

CN102711916A RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

IN200800733P1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

IN265497B RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP1919916B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP2256118B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP1919916A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP1919916B8 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP2256118A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP2523731A1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

EP2523731B1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent Jan, 2031

(8 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms Oct, 2035

(13 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

2. Drug name - NEOPROFEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337 RECORDATI RARE Ibuprofen compositions and methods of making same
Mar, 2032

(9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) INJECTABLE;INTRAVENOUS Prescription

3. Drug name - SIGNIFOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8299209 RECORDATI RARE Pharmaceutical composition comprising cyclic somatostatin analogues
Dec, 2025

(3 years from now)

US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(4 years from now)

CN1267451C RECORDATI RARE Somatostatin Analogues
Jul, 2021

(1 year, 2 months ago)

CN1446229A RECORDATI RARE Somatostatin Analogues
Jul, 2021

(1 year, 2 months ago)

CN1812997A RECORDATI RARE Pharmaceutical Composition
Jun, 2024

(1 year, 8 months from now)

CN1812997B RECORDATI RARE Parenteral Pharmaceutical Compositions Comprising Somatostatin Analogues
Jun, 2024

(1 year, 8 months from now)

IN200300143P4 RECORDATI RARE Somatostatin Peptidomimetics
Jul, 2021

(1 year, 2 months ago)

IN204073B RECORDATI RARE Somatostatin Peptidomimetics
Jul, 2021

(1 year, 2 months ago)

IN200503498P4 RECORDATI RARE Pharmaceutical Composition
Jun, 2024

(1 year, 8 months from now)

IN229591B RECORDATI RARE Parenteral Pharmaceutical Composition Comprising Somatostatin And Tartaric Acid
Jun, 2024

(1 year, 8 months from now)

EP1648934A2 RECORDATI RARE Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues
Jun, 2024

(1 year, 8 months from now)

EP1648934B1 RECORDATI RARE Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues
Jun, 2024

(1 year, 8 months from now)

EP1307486B1 RECORDATI RARE Somatostatin Analogues
Jul, 2026

(3 years from now)

EP1307486A2 RECORDATI RARE Somatostatin Analogues
Jul, 2026

(3 years from now)

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription
EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription
EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

4. Drug name - SIGNIFOR LAR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(4 years from now)

CN1267451C RECORDATI RARE Somatostatin Analogues
Jul, 2021

(1 year, 2 months ago)

CN1446229A RECORDATI RARE Somatostatin Analogues
Jul, 2021

(1 year, 2 months ago)

IN200300143P4 RECORDATI RARE Somatostatin Peptidomimetics
Jul, 2021

(1 year, 2 months ago)

IN204073B RECORDATI RARE Somatostatin Peptidomimetics
Jul, 2021

(1 year, 2 months ago)

EP1307486B1 RECORDATI RARE Somatostatin Analogues
Jul, 2026

(3 years from now)

EP1307486A2 RECORDATI RARE Somatostatin Analogues
Jul, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues Aug, 2023

(10 months from now)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues Oct, 2026

(4 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles May, 2028

(5 years from now)

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 20MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 30MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 40MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription
EQ 60MG BASE/VIAL FOR SUSPENSION;INTRAMUSCULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.